Parathyroid Disorders Market: Trends, Share, and Segmentation Insights

- January 14, 2025

1. Parathyroid Disorders Market Overview

The parathyroid disorders market encompasses the diagnosis, treatment, and management of conditions affecting the parathyroid glands, four small glands located on the back of the thyroid gland. These glands regulate calcium levels in the blood. The primary disorders include hyperparathyroidism (overactive parathyroid glands) and hypoparathyroidism (underactive parathyroid glands). The market includes pharmaceuticals, medical devices, surgical procedures, and diagnostic tests.

2. Parathyroid Disorders Market Drivers

Increasing Prevalence: The prevalence of parathyroid disorders, particularly hyperparathyroidism, is increasing due to an aging population and improved diagnostic techniques.
Technological Advancements: Advances in minimally invasive surgical techniques, such as minimally invasive parathyroidectomy (MIP), are driving market growth by improving patient outcomes and reducing recovery time.
Development of Novel Therapies: Research and development of new medications and therapeutic approaches for parathyroid disorders, including targeted therapies and gene therapies, are creating new market opportunities.
Rising Healthcare Expenditure: Increased healthcare spending globally is enabling greater access to diagnostic tests and advanced treatments for parathyroid disorders.

3. Parathyroid Disorders Market Restraints

High Treatment Costs: Surgical procedures and advanced diagnostic tests can be expensive, potentially limiting access to care for some patients.
Lack of Awareness and Early Diagnosis: Insufficient awareness among healthcare providers and the general public about parathyroid disorders can lead to delayed diagnosis and suboptimal treatment.
Side Effects of Medications: Some medications used to treat parathyroid disorders can have side effects, which may limit their use in certain patient populations.
Reimbursement Challenges: Obtaining insurance coverage for certain diagnostic tests and treatments can be challenging for some patients.

4. Parathyroid Disorders Market Opportunities

Development of Novel Therapeutics: Research and development of novel therapies, including gene therapies and targeted therapies, for the treatment of parathyroid disorders offer significant growth potential.
Telemedicine and Remote Monitoring: Telemedicine can improve access to care for patients in remote areas and facilitate remote monitoring of treatment outcomes.
Personalized Medicine: Tailoring treatment plans to individual patient characteristics, such as age, comorbidities, and genetic factors, can improve treatment outcomes and reduce side effects.
Artificial Intelligence (AI) in Diagnosis: AI-powered tools can assist in the diagnosis and risk stratification of parathyroid disorders, leading to earlier detection and more effective treatment.

5. Parathyroid Disorders Market Key Players

Amgen Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Shire (part of Takeda Pharmaceutical Company) (Ireland), Roche Holding AG (Switzerland), Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (United States), Ascendis Pharma A/S (Denmark), Kyowa Kirin Co., Ltd. (Japan), Amryt Pharma (Ireland)

6. Parathyroid Disorders Market Segmentation

By Type : Hyperparathyroidism, Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism, Hypoparathyroidism

By Diagnosis: Blood Tests, Imaging Tests, Bone Density Tests

By Treatment: Medications, Surgery, Hormone Replacement Therapy, Dietary Management

By End-Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings.

7. Parathyroid Disorders Market Regional Analysis

Asia-Pacific, Europe, North America, Latin America, Middle East & Africa

8. Parathyroid Disorders Market Recent Developments

New Drug Approvals: Recent approvals of new medications for the treatment of parathyroid disorders.
Technological Advancements: Development of minimally invasive surgical techniques, advanced imaging modalities, and novel diagnostic tools.
Clinical Trials: Ongoing clinical trials evaluating the efficacy and safety of new therapies for parathyroid disorders.
Mergers and Acquisitions: Strategic mergers and acquisitions among key players in the market to expand product portfolios and enhance market presence.
Focus on Digital Health: Integration of digital health technologies, such as telemedicine and remote patient monitoring, into the management of parathyroid disorders.